Article Text

Download PDFPDF

Protocol for a prospective longitudinal study of risk factors for hypertension incidence in a Mexico City population: the Tlalpan 2020 cohort
  1. Eloisa Colín-Ramírez1,
  2. Susana Rivera-Mancía1,
  3. Oscar Infante-Vázquez2,
  4. Raúl Cartas-Rosado1,
  5. Jesús Vargas-Barrón3,
  6. Magdalena Madero4,
  7. Maite Vallejo5
  1. 1 National Council for Science and Technology (CONACYT) – National Institute of Cardiology ‘Ignacio Chávez’, Juan Badiano 1, Sección XVI, Mexico City, Mexico
  2. 2 Department of Electromechanical Instrumentation, National Institute of Cardiology ‘Ignacio Chávez’ Juan Badiano 1, Sección XVI, Mexico City, Mexico
  3. 3 Division of Research, National Institute of Cardiology ‘Ignacio Chávez’ Juan Badiano 1, Sección XVI, Mexico City, Mexico
  4. 4 Department of Nephrology, National Institute of Cardiology ‘Ignacio Chávez’ Juan Badiano 1, Sección XVI, Mexico City, Mexico
  5. 5 Department of Social Medicine Research, National Institute of Cardiology ‘Ignacio Chávez’, Juan Badiano 1, Sección XVI, Mexico City, Mexico
  1. Correspondence to Dr Maite Vallejo; maite_vallejo{at}yahoo.com.mx

Abstract

Introduction Systemic hypertension (HTN) is a common risk factor for cardiovascular disease. In Mexico, HTN prevalence has increased over time and is currently 31%. Nonetheless, information about the country's HTN incidence and its associated risk factors is scarce. Understanding this condition is a priority for identifying the scope of primary prevention. The main objective of this study is to evaluate the effect of traditional and non-traditional risk factors on the incidence of HTN in a cohort of healthy Mexico City residents under biannual follow-up for 10 years.

Methods and analysis A prospective longitudinal study is proposed in which clinically healthy residents of Mexico City between 20 and 50 years old will be recruited; the participants will be evaluated every 2 years over a period of 10 years or until they develop HTN. Evaluations regarding sociodemographic, clinical, anthropometric, biochemical, diet, physical activity, stress, sleep quality, alcohol and tobacco consumption factors will be performed. The participants will be recruited from the 16 municipalities of Mexico City through promotional strategies aimed at the community and will be clinically evaluated at a tertiary care institution, Instituto Nacional de Cardiología Ignacio Chávez (National Institute of Cardiology Ignacio Chavez), located in Mexico City, Mexico. Sample size estimated for this study is 3436, and the Cox proportional hazards model will be used to estimate HRs for the association between explanatory variables and HTN using both raw and adjusted data.

Ethics and dissemination This study was approved by the Institutional Bioethics Committee of the Instituto Nacional de Cardiología Ignacio Chávez (National Institute of Cardiology Ignacio Chavez) under number 13-802. Findings from this study will be disseminated through scientific papers and research conferences.

  • hypertension
  • incidence
  • risk factors
  • Mexico
  • cohort

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors ECR contributed to the study design and drafted the manuscript; SRM contributed to design the system of management and storage of biological samples and drafted the manuscript; OIV contributed to the design and conception of the study; RCR contributed to the design of the data capture system and drafted the corresponding section of the manuscript; JVB contributed to the design and conception of the study; MM contributed to the design and conception of the study; MV contributed to the conception and design of the study and drafted the manuscript. In addition, all authors read and approved the final manuscript.

  • Funding This project is funded by the Consejo Nacional de Ciencia y Tecnología (CONACYT) (National Council for Science and Technology) under the ‘Cátedras CONACYT’ programme, No 1591. Funding was also received from AstraZeneca Mexico (collaboration agreement without number).

  • Competing interests None declared.

  • Patient consent This manuscript does not contain any personal medical information about an identifiable living individual. Data from participants of this study are anonymised. Each participant signs the informed consent approved by the Institutional Bioethics Committee of the Instituto Nacional de Cardiología Ignacio Chávez (National Institute of Cardiology Ignacio Chavez) under number 13-802.

  • Ethics approval This study was approved by the Institutional Bioethics Committee of the INCICh under number 13-802. Written informed consent will be obtained from all participants for inclusion in the main study and the genetic substudy.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles